AUTHORS
Melvin Edward Thomas III, PhD, Jeffery M. Klco, Member; Director, Division of Hematopathology and Molecular Pathology2, Emily Xiong3, Haley Writt4, Tamara Westover, BS5, Mike Walsh, PhD6, Jing Ma, PhD7, Chandra Rolle8, Yonghui Ni9, Laura Janke10, Stan Pounds, PhD11
AFFILIATIONS
1 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
2 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
3 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
4 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
5 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
6 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
7 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
8 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
9 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
10 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
11 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
ABSTRACT
Germline mutations in SAMD9 (sterile alpha motif domain containing 9) and SAMD9L (SAMD9-like) represent a rare genetic predisposition that accounts for 8-17% of children with MDS and bone marrow failure (BMF) syndromes. SAMD9/SAMD9L are interferon-inducible genes, and it’s hypothesized that infection-mediated upregulation precipitates BMF. Deletions involving chromosome 7, which contain the SAMD9/SAMD9L locus, is a recognized compensation mechanism in patients. We’ve shown previously in a genetically engineered mouse model (Samd9l-W1171R/Vav1-cre, referred to as Samd9l-Mut), that inflammation synergizes with the physiological effects of mutant Samd9l expression to enhance the development of BMF. Based on these preliminary studies, we hypothesize that targeting inflammatory pathways will rescue Samd9l-mutant-dependent BMF, HSPC fitness defects, and Samd9l mutant-dysregulated pathways.
We’ve shown previously that Samd9l-Mut mice have an incomplete penetrance with ~68% of mice surviving up to 300 days. Here we demonstrated that an acute dose of polyinosinic:polycytidylic acid (pIpC), to induce an interferon response, significantly decreased the median overall survival (128 days, log-rank p < 0.001) of Samd9l-Mut mice. Histologic examination confirmed bone marrow aplasia, while immunophenotyping showed a depletion of LT-HSCs, alongside most of the HSPC compartment. Bulk RNA-seq of HSPCs highlighted dysregulation of several known key pathways, such as cell cycle and translation. This was further supported by in vitro translation assays, which revealed a further decrease in translation in Ifnα-treated Samd9l-Mut HSPCs.
To determine if targeting upstream inflammatory pathways could rescue the phenotypes of HSPCs in Samd9l-Mut mice, we crossed our Samd9l-Mut strain with (B6(Cg)-Ifnar1tm1.2Ees/J) (Samd9l-Mut-Ifnar1-KO) to remove type 1 interferon signaling. In vitro translation assays showed that Samd9l-Mut-Ifnar1-KO HSPCs have increased translation when compared to Samd9l-Mut HSPCs. We’ve previously reported that Samd9l-Mut expression causes a significant reduction in HSPC fitness. To this aim, in vivo competitive transplantation assay at a 5:1 donor:competitor ratio was performed to determine if Ifnar1-KO can rescue this fitness disadvantage. Immunophenotyping of blood chimerism was assessed monthly up to 16-weeks, which revealed that Samd9l-Mut-Ifnar1-KO HSPCs have a rescue in engraftment (25.2%) when compared to Samd9l-Mut HSPCs (2.8%), but not to the level of Samd9l-WT (87.9%). We next assessed the hematopoietic compartment via immunophenotyping and scRNA-seq to determine if Samd9l-Mut-Ifnar1-KO mice are protected against the effects of acute inflammation induced by pIpC. Samd9l-Mut-Ifnar1-KO mice had normal BM cellularity and a rescued HSPC compartment compared to the near completely ablated HSPC compartment in pIpC treated Samd9l-Mut mice. scRNA-seq revealed that the hematopoietic compartment in pIpC-treated Samd9l-Mut mice was skewed towards an early erythroid-like progenitor cell population, which was not observed in pIpC-treated Samd9l-Mut-Ifnar1-KO mice. We also observed a near-complete rescue of overall survival of pIpC-treated Samd9l-Mut-Ifnar1-KO mice (~94%) compared to treated Samd9l-Mut mice, which had an overall survival of 36.7% and a median overall survival of 128 days (log-rank p < 0.001). Lastly, we targeted inflammation with a 4-week treatment with ruxolitinib followed by in vivo competitive transplantation at a 5:1 donor:competitor ratio. Immunophenotyping of blood chimerism was assessed monthly up to 16-weeks, and we observed that ruxolitinib-treated Samd9l-Mut HSPCs showed improved engraftment (29.2%), when compared to vehicle-treated Samd9l-Mut HSPCs (0.84%), but not to the level of Samd9l-WT (94.1%).
Our data demonstrate that inflammation synergizes with the cytotoxic effects of Samd9l-Mut expression to disrupt the HSPC compartment and induce BMF. We show that genetic targeting of inflammatory pathways in Samd9l-Mut mice can increase HSPC fitness, rescue Samd9l-Mut-dependent BMF, and promote survival. Lastly, we provide a therapeutic approach that can partially rescue the HSPC fitness disadvantage, suggesting a potential strategy for SAMD9/SAMD9L syndrome patients with further development.
DISCLOSURES
Melvin Edward Thomas III, PhD: No relevant conflicts of interest to declare.